PamGene
PamGene, Alithea Genomics, Lausanne University get €1M for Pan-Cancer Blood Test
The Dutch-Swiss Mainline consortium plans to develop a multiomics model to guide immune checkpoint inhibitor therapy across a broad range of cancers.
PamGene Gains CE-IVD Registration for Immunotherapy Guidance Tests
The company's blood-based IOpener-NSCLC and IOpener-melanoma assays help guide therapy in non-small cell lung cancer and advanced melanoma patients, respectively.
In Brief This Week: Biocept, SeqLL, Castle Biosciences, VolitionRx, More
News items for the week of March 28, 2022.
European Consortium Nets €1M for Test to Predict Bladder Cancer Immunotherapy Response
The Eurostars grant will allow PamGene, Novigenix, and Radboud University Medical Center to develop a liquid biopsy test using mRNA and kinase activity profiling.
This story was originally posted on April 27.